Best myeloma crowd podcasts we could find (Updated June 2017)
Related podcasts: Immunotherapy Multiple Myeloma Myeloma Mpatient Health Health and Well-Being  
Myeloma crowd public [search 0]
show episodes
 
M
Myeloma Crowd Radio
Monthly+
 
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
 
Loading …
show series
 
Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system's T cells. This is called a bi-specific antibody, going after ...…
 
Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely ...…
 
Today's myeloma therapy can help patients gain remission, but the combinations can cause their own side effects because they target normal cells as well as cancer cells. Investigators at the University of Iowa including Dr. Guido Tricot and Dr. Frank Zhan have tested mega-doses of Vitamin C in combination with the standard chemo melphalan and f ...…
 
Dr. Gareth Morgan of the UAMS Myeloma Institute joins us to share more about the Myeloma Genome Project, a global effort to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve diagnosis, prognosis and treatment. The project will compile a broad set of genetic data and resulting outcomes ...…
 
About 10-20% of multiple myeloma patients will develop a condition called amyloidosis during the course of their disease. Amyloidosis is a disease caused by protein buildup in organs such as the heart, kidneys, liver or intestines, leading to organ damage and complications associated with some multiple myeloma treatments. There are three major ...…
 
Allogeneic stem cell transplant is rarely used in multiple myeloma treatment, but for younger patients with high-risk myeloma, it could be a highly effective strategy with durable outcomes. Dr. Cristina Gasparetto from Duke University shares the rationale of this approach for a subset of myeloma patients and how improvements in reducing allo si ...…
 
For the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If ...…
 
The year 2017 promises to be an exciting one in multiple myeloma research. With so many new types of therapies in the clinic like immunotherapies, specific inhibitors and variations of combinations, the choices are expanding for myeloma patients. Listen to myeloma expert Dr. Robert Z. Orlowski of the MD Anderson Cancer Center as he reviews the ...…
 
It's a rare opportunity to have a panel of myeloma experts available to answer any myeloma patient question. Experts at our Myeloma Crowd Round Tables answered common patient questions at our meeting in St. Louis. Listen in to learn more about a wide variety of topics with experts that have over 80 years treating myeloma including: Guido Tricot ...…
 
One of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical ...…
 
At the University of Michigan, Dr. Craig Cole is working on a collaboration with the MMRC to perform genomic sequencing on 500 hundred relapsed and refractory myeloma patients over a two year period. The goal is to share each patient's genomic profile to identify patient-specific treatment options. The study will be open at 11 myeloma academic ...…
 
According to multiple myeloma specialists, autologous stem cell transplant is not going away any time soon, even in the age of new therapies. Dr. Sergio Giralt is a myeloma specialist and a transplant specialist who shares what "transplant plus" could look like. Now that new treatments and drugs are in the clinic, what is being done to extend r ...…
 
How do clinical trials work in multiple myeloma? Dr. Nikoletta Lendvai of the Memorial Sloan Kettering Cancer Center joins us to share information how how trials work, how patients can join and why they benefit by participating. She will also describe open clinical trials at her center including a new drug called Selinexor. Listen in and learn ...…
 
What can multiple myeloma patients try if they relapse current medications or treatments early? Or if the relapses continue and they become refractory to treatment? With newer drugs now available in the clinic, picking the right combinations at the right time is key for patients. Learn how to educate yourself about the current options and how t ...…
 
Now that daratumumab is being used in the clinic, myeloma specialists have more experience with its use. Learn why a new test is in the works to prevent patients from being taken off the drug when they are actually responding and which combinations are the most effective. Dr. Torben Plesner has been running daratumumab clinical trials since its ...…
 
For over sixty years Dr. Robert Kyle, MD of the Mayo Clinic led the way in myeloma research and was the pioneer that defined and determined early precursor conditions MGUS and smoldering myeloma in the late 1970s and early 1980s. He joins us to share over 40 years of data from an extensive longitudinal study and his key findings on these precur ...…
 
One year ago, we began raising funds for the Myeloma Crowd Research Iniatiive. With the help of an expert Scientific Advisory Board and a knowledgeable Patient Advisory Board, we selected two projects to fund: 1) a CAR T Cell research project targeting CS1 and BCMA from Drs. Hermann Einsele and Michael Hudecek from the University of Würzburg in ...…
 
Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies showing greater overall survival and with new drugs and immunotherapies in the mix, what can we add on the front or ...…
 
Nanotecnology is the study of very small things - won to the atom and molecule level. Researchers at Washingon University have been given a prestigious grant by the NIH to study nanotechnology in cancer and more specifcially, in multiple myeloma. Nanotechnology can deliver a higher concentration (by a hundred fold) of drug in a more targeted wa ...…
 
You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they are best used from Dr. Don Benson, MD, PhD, an immunotherapy expert who has been actively researching this ...…
 
The Institute for Clinical and Economic Review’s (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis “to discuss the comparative clinical effectiveness and value of therapies of multiple myeloma.” The goal is to create recommendations that health insurers (or payers) w ...…
 
While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma ...…
 
Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may not affect the myeloma stem cells. Dr. Matsui recently presented results from a study he did with colleagues at Johns ...…
 
Melanie House, DPT, NCS of the University of Iowa recently presented at Pat's Myeloma Survival School on physical issues that myeloma patients face before, during and after their treatment. As part of the Muscles for Myeloma series, she will give practical, real-world advice to make life more manageable for patients: How to rebuild strength dur ...…
 
The multiple myeloma aresenal is growing, giving myeloma experts more tools to combat the complex blood cancer, multiple myeloma. Learn how investigators like Dr. David Siegel, MD, PhD of the John Theurer Cancer Center are vetting treatment combinations using clinical trials to identify optimal treatment paths, especially for patients who are f ...…
 
Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are waiting until progression to treat when we have newer non-toxic therapies to use. Dr. Ghobrial shares her Prevention of Progression Clinic's efforts to keep myeloma at bay. In this show, she shares her open study (observationa ...…
 
Immunotherapy combinations are just beginning. At the ASH 2015 conference Dr. David Avigan, MD of the Beth Israel Deaconess Medical Center shared his work to use a vaccine with an additional immunotherapy (a PD-1 blocker) and autologous transplant to make the transplant more durable and eliminate minimal residual disease. Learn more about this ...…
 
Some treatments for multiple myeloma have been used for over two decades. With all of excitement around new treatments like immunotherapies, how do these two different worlds converge or collide? Learn from Dr. Muzaffar Qazilbash, MD of the MD Anderson Cancer Center about the utility of stem cell transplant in the age of immunotherapy and how t ...…
 
Multiple myeloma is typically tracked by measuring the M-protein, also called the "M-spike." But in some patients, the M-protein gets lost, making it difficult if not impossible to detect myeloma levels without a bone marrow biopsy. Dr. James R. Berenson, MD of the Institute for Myeloma & Bone Cancer Research has been working on a new test (ass ...…
 
The advances found for multiple myeloma over the past two decades have been extroardinary. Much has been learned, and much has been accomplished with new treatment developments and arguably more discoveries than other cancers in the same time period. The past is impressive for this complex cancer, but there is more work to do. Dr. Ken Anderson ...…
 
JSK is the first in its class with a new and unique method of killing multiple myeloma. It has a broad-spectrum anti-cancer activity, especially for myeloma and AML (acute myeloid leukemia) but is not toxic for normal cells. The JSK product is running through the standard approval process and is now in an advanced stage of pre-clinical developm ...…
 
What happened at this year's American Society of Hematology (ASH) meeting in Orlando Florida? With three new drugs approved just before the start of the conference, there is so much to understand and absorb. Listen to Dr. Orlowski, MD, PhD of the MD Anderson Cancer Center give a simple explanation of the improvements in myeloma and some of his ...…
 
New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Wo ...…
 
Treatment for multiple myeloma is all about the combinations. Recently we've been hearing about the "BIRD" combinations. What are they and how effective are they? Learn from Dr. Tomer Mark, MD, MSc from Weill Cornell Medical Center about this new combination and what it means for myeloma patients.
 
With the explosion in immunotherapies for multiple myeloma, we have heard there are "windows" of best and most effective use. What are those windows and when is the best time to use these new approaches? The field is ever growing and Dr. Djordje Atanackovic will share how and when to use these new tools for a myeloma patient's best care. Thanks ...…
 
The University of Pennsylvania had tremendous results with a recent clinical trial using a CAR T cell treatment targeting CD19 for a myeloma patient. The results were so impressive that some wonder if they have been able to eliminate the myeloma stem cell clone for one patient who had relapsed 9 therapies and had a high-risk genetic feature. Le ...…
 
Immunotherapies are making their way into the clinic and as they do, more exciting options will be available for patients. Researchers are now studying the best possible way to leverage the standard and effective multiple myeloma treatments with ways to empower the immune system to fight myeloma. Learn what Dr. Daniel Fowler, MD of the NIH is d ...…
 
Dr. Don Benson, MD, PhD of The James Cancer Center at Ohio State University is a multiple myeloma specialist with deep expertise in immunotherapy. He shares the growing and exciting world of immunotherapies in multiple myeloma - how they work and how they are opening up an exciting new set of opportunities for myeloma patients.…
 
Social media tools can be used by doctors and patients to speed the time to cure, especially for rare diseases like multiple myeloma. Learn from myeloma specialist and oncologist Dr. Mike Thompson, MD, PhD from the Aurora Health Care how he is driving social media adoption in oncology to increase the speed for the discovery of a cure and what t ...…
 
Could an MRI predict how a multiple myeloma patient's disease will progress and respond to treatment? Learn what Dr. Jens Hillengass, MD of the University of Heidelberg is doing to use the latest in imaging techniques to learn more about an individual patient's myeloma and what it means for their outcomes and care.…
 
The University of Pennsylvania has led the charge in the US for CAR T cells for blood cancers with impressive results in leukemia. Dr. Alfred Garfall, MD was recently covered in Targeted Oncology for his research using CD19 in multiple myeloma. Learn more about the lessons learned in leukemia and how the exciting field is expanding and maturing ...…
 
Could multiple myeloma genetics give us clues into who will respond to standard treatments and who will not? Dr. Brian Van Ness, PhD of the University of Minnestota shares his study to do just that. In a collaboration between the Unversity of Minnesota and the Mayo Clinic, Dr. Van Ness will describe his study to determine who will respond to tr ...…
 
The measles virus used successfully for a patient with relapsed myeloma is now a well known and exciting story shared on maintstream media. Dr. Frits van Rhee MD PhD MRCP, FRCPath and Dr. Stephen Russell, MD PhD FRCP, FRCPath take the success one step further with a Phase II trial of the measles virus with further engineering in patients with r ...…
 
CAR T cell therapy is a new and exciting potential treatment approach in blood cancers. It is a highly personalized treatment because the patient's own T-cells are redirected to erradicate cancerous cells after a single infusion, allowing patients to avoid the chronic side effects of long-term, toxic chemoradiotherapy. Learn more about Dr. Herm ...…
 
UAMS has led the way in studying the biology of myeloma cells to find new therapies. We now know that multiple myeloma patients can have a variety of types of myeloma cells at the time they are diagnosed - some with more aggressive features than others. Researchers have found that patients with several different types of myeloma cells at diagno ...…
 
Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Lea ...…
 
Myeloma is not a single disease. Two types of high-risk myeloma have swapped chromosomes (14;16) and (14;20) have notoriously short survival times with conventional treatments and are found to be resistant to bortezomib, one of the standard myeloma therapies. Dr. Frank Zhan, MD, PhD of the University of Iowa searched a genetic database to ident ...…
 
Dr. Ivan Borrello, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, joins us as part of the top 10 projects selected by the Myeloma Crowd Research Initiative. He shares his pioneering work using patients' own immune cells to fight their cancer. His group leads the research for this type of immunotherapy, called adaptive T-c ...…
 
Join us for our fourth episode of the new Myeloma Crowd Research Initiative of the proposals under consideration for the MCRI patient-led funding initiative. Dr. Bruno Paiva, PhD, is a multiple myeloma researcher from the University of Navarra Spain specializing in minimal residual disease (MRD) detection using flow cytometry. What does the new ...…
 
The third in our Myeloma Crowd Radio series for the new Myeloma Crowd Research Initiative (MCRI), we talk with Dr. Robert Orlowski, MD, PhD at MD Anderson Cancer Center about work being done specifically for the highest risk multiple myeloma patients with del17p. This is a genetic feature with historically poor outcomes. Learn more about the hy ...…
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login